IMPORTANCE Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset of patients. Clinical outcomes after treatment by immunotherapy can be influenced by the host's immune system. The immune system is modified with age by age-related immune dysfunction. 74.8 [6.9] years). Mean follow-up duration starting at treatment initiation was 12.5 months. Patients older than 65 years treated with immunotherapy had a better mean progression-free survival (4.8 vs 3.4 months; P = .04) and overall survival (not reached vs 10.1 months; P = .009) than younger patients in univariate analysis, and after adjusting on prognosis covariates. This was particularly true with patients treated with anti-programmed cell death protein 1. Common immune-related adverse effects were similar in both cohorts.
In the preclinical setting, age-related immune dysfunction has been shown to affect response to immune checkpoint inhibitors. 4 In this study, we sought to evaluate if age affects response and tolerance to immunotherapy in patients treated for metastatic melanoma, in a real-life setting.
Methods

Setting and Participants
Inclusion criteria for this study were patients with unresectable or metastatic melanoma treated from January 2007 to February 2016 with ipilimumab, nivolumab, or pembrolizumab in the dermatology department of the Lyon Sud University Hospital in Pierre Bénite, France. Eligible patients were screened by interrogating 2 prospective databases: Melbase and PAIR (Programme d'Actions Intégrées de Recherche) Melanoma. Melbase is a French multi-institution database that follows patients with unresectable stage III and IV melanoma (NCT02828202), PAIR is a singleinstitution database that follows patients treated with nivolumab as a second-line treatment in the dermatology department of the Lyon Sud University Hospital (NCT02626065). All patients gave their written informed consent to be included in these databases; the study was authorized by the ethical review board of the Hospices Civils de Lyon. Patients were not compensated for their participation.
Data Collection
Data collection was performed retrospectively using electronic medical records by 2 dermatologists (A.B. and M.P.M.). Patient characteristics included age at treatment initiation, sex, presence or absence of autoimmune diseases, and cumulative illness rating score (CIRS). Eastern Cooperative Oncology Group performance status and body mass index were collected prior to treatment with immunotherapy and at first assessment of treatment response. Melanoma characteristics at diagnosis included Breslow index, genotype, results of sentinel lymph node biopsy, presence or absence of ulceration, and melanoma subtype.
Treatment characteristics included American Joint Committee on Cancer stage at treatment initiation, number of metastatic sites prior to treatment, presence or absence of brain metastasis, number and type of prior treatments, date of treatment initiation, treatment dosage, concomitant use of oral corticosteroids (defined as prescription of >20 mg of oral corticosteroids for more than 10 days) or immunosuppressants, date of clinician-based progression, and date of death or last control.
Biological blood parameters collected to prior treatment were lactate dehydrogenase, C-reactive protein, albumin, and creatinine levels and complete blood cell count.
Data collected to evaluate drug toxic effects included the presence or absence of diarrhea during treatment, cutaneous eruption, thyroid modifications, hepatitis, hypophysitis, vitiligo, and other, with patients' date of diagnosis and their tumor grading from 1 to 4 according to National Cancer Institutes-Common Terminology Criteria for Adverse Events, version 3.0.
Clinical and serological follow-up was scheduled every 2 or 3 weeks during treatment. Radiological follow-up was scheduled every 3 months.
Statistical Analysis
The characteristics of patients in the 2 age groups were compared using 2-tailed univariate analysis. Fisher exact test was used to compare qualitative variables as appropriate. Mann-Whitney test was used to compare quantitative variables as appropriate.
Primary end points were overall survival (OS) and progression-free survival (PFS); OS was defined as the time from treatment initiation to death from any cause, and PFS was defined as the time from treatment initiation to progressive disease or death from any cause, whichever came first. Probabilities of survival were calculated using Kaplan-Meier estimates and compared using 2-tailed log-rank test. Covariates, including age, were considered statistically associated with PFS or OS if the associated P value was less than 0.05. All variables with a statistically significant impact on PFS or OS in univariate analysis were included in multivariate Cox proportional hazard models. Then variable selection was done using a stepwise backward procedure.
Secondary end points were percentage of immune-related adverse events and type of adverse events according to patient's age. All analyses were performed using R statistical software (R Foundation for Statistical Computing). Database follow-up was closed in August 2016. Data were rarely missing, and no data imputation was performed through the analyses.
Results
Patients and Treatment Characteristics
Ninety-two patients were eligible and included in this study for a total of 120 lines of treatment. Fifty-four patients were included in the cohort 65 years or younger, and 38 patients were included in the cohort older than 65 years.
Patient characteristics, as seen in Table 1 ; and eTable 1 in the Supplement, were similar in both age groups except for CIRS comorbidity score (P < .001), the duration between initial diagnosis and first systemic treatment (P = .01), C-reactive protein dosage (P = .001), and neutrophil count (P = .01).
Key Points
Question Does age influence clinical outcomes and tolerance to immunotherapy in metastatic melanoma?
Finding In this retrospective cohort study in a real-life setting, patients older than 65 years treated by immunotherapy for a metastatic melanoma had a better mean progression-free survival (4.8 vs 3.4 months) and overall survival (not reached vs 10.1 months) than younger patients. Common immune-related adverse effects were similar in both cohorts.
Meaning Age might be associated with a better clinical outcome after treatment with immunotherapy in the real-life setting, and older patients did not have more immune-related adverse events.
Mean follow-up duration starting at treatment initiation was 12.5 months.
Patient Outcomes
Patients older than 65 years treated with immunotherapy (ipilimumab and anti-programmed cell death protein 1 [PD-1]) had a better PFS (4.8 vs 3.4 months; P = .04) and OS (10.1 months vs not reached; P = .009) than patients 65 years or younger (Figure) . These results were confirmed in subgroup analysis selecting patients treated with either ipilimumab or anti-PD1 (eFigure 1 and 2 in the Supplement). Multivariate analysis showed that age was independently associated with a better OS and PFS (eTables 2 and 3 in the Supplement).
Toxic Effects in Patients
No difference in frequency or grade of immune adverse events (IAEs) was observed between younger and older patients ( Table 2) , even though older patients had more comorbidities (Table 1) . 
Discussion
In our study, older patients treated by immunotherapy had the same incidence of common IAEs as younger patients. The expansion of protective regulatory mechanisms, such as a higher production of peripheral T-regulatory cells, could contribute to limit IAEs in older patients. 5 In our single-institution, retrospective study, patients treated for metastatic melanoma who were older than 65 years had better OS (not reached vs 10.1 months; P = .009) and PFS (4.8 vs 3.4 months; P = .04) compared with patients 65 years or younger. This association between older age and a better prognosis was independent of other prognosis covariates, and was stronger for patients treated with anti-PD-1 compared with patients treated with ipilimumab. In our study, the biological mechanisms that might contribute to better responses in older patients were not evaluated. A high level of Il-2 soluble receptor at baseline, high levels of myeloid derived suppressor cells, a low neutrophil count, absence of ICOS+ CD4-positive T lymphocyte induction, high PD-L1 expression by the tumor, high PD1 expression on CD8-positive T cells, and CD8-positive T-cell tumor infiltration, have been shown to influence clinical responses to immunotherapy, and have been observed in the presence of ARID. 4, [6] [7] [8] In addition, gut microbiota is known to influence responses to immunotherapy and could account for age-related differences in response to treatment, as it can be modified by age.
9 Finally, differences in pharmacokinetic parameters, like drug clearance and drug exposure, that can be modified by sarcopenia, renal dysfunction, and polymedication 10,11 could also explain differences in immunotherapy efficiency.
Limitations
Our study is limited by its monocentric and retrospective nature and its small sample size. However, compared with previous clinical trials 1,2,12-14 and meta-analysis, 8,15 it might be more reflective of current practice, as our patients were unselected and therefore tended to have more polymedication, more prior treatments, and more severe diseases than in clinical trials.
Conclusions
In this real-life, single-institution retrospective study, an age greater than 65 years was not associated with more IAEs in patients treated by immunotherapy for metastatic melanoma, confirming that age should not be a limiting factor for immunotherapy. 
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Dermatology's Grandest Piano
Sarolta Kárpáti, MD; Leonard J. Hoenig, MD This is a story about a piano that played a small but special role in dermatology's history. It belonged to Stephen Rothman, MD (1894-1963), one of the most influential dermatologists of the 20th century. He was also an accomplished pianist. Rothman was born in Budapest, Hungary, into a Jewish family, although he later became a Roman Catholic. His mother had musical abilities that were reflected in her son's growing passion for the piano. Rothman was torn between becoming a musician or a physician. Fortunately for dermatology, he chose the latter.
Rothman was a rising star in Hungarian dermatology. In 1935 he served as Secretary-General of the Ninth International Congress of Dermatology, which was held in Budapest. The conference was a huge success, but the future of dermatology in Hungary became clouded as the world soon turned to war and Hungary allied itself with Nazi Germany. Anti-Semitic laws in Hungary curtailed Rothman's ability to practice dermatology, but he was able to escape to the United States in 1938. Unfortunately, many Jewish dermatologists remained in Hungary, only to perish during the Holocaust. 1 In America, Rothman restarted his academic career at the University of Chicago, where he became chief of the dermatology section and professor of dermatology. In 1954 he published his landmark text,
Physiology and Biochemistry of the Skin.
As a pianist, Rothman enjoyed playing Chopin, Schubert, Schumann, and Mozart at dermatology meetings. Mozart, however, was his specialty, and he even wrote an article for this journal in 1945 that discussed Mozart's childhood affliction with erythema nodosum. Today, Dr Rothman's piano sits quietly at the Department of Dermatology, Venereology, and Dermatooncology, Semmelweis University, in Budapest. The piano is a reminder of past times when dermatologists from all backgrounds learned together at conferences while enjoying each other's company. Maybe one day, people will put aside hatred and prejudice, as they gather around the pianos of the world to enjoy good music in a spirit of brotherhood and peace. 
